The molecular diagnostic application that detects clinically relevant gene fusions and exon skipping events in lung cancer samples by combining a capture-based target enrichment kit with the analytical capabilities and advanced features of the SOPHiA DDM™ Platform.

Main Features

The SOPHiA DDM™ Dx RNAtarget Oncology Solution is intended to be used to identify clinically relevant gene fusions in 11 genes and exon skipping events in EGFR and MET in RNA extracted from FFPE samples of patients with diagnosed lung cancer by targeting specific transcripts. The function of the product is to provide an aid to healthcare professionals to make clinical decision(s) related to gene fusions/exon skipping events and to provide molecular rationale for the appropriate disease management strategy. The product is a semi-automated, qualitative device intended to be used as an in vitro diagnostic for professional use only.

One Simple Intuitive Platform: Beyond Analytics

Accelerated assessment and reporting of genomic variants

The SOPHiA DDM™ Platform provides the user with a web-based portal and workspace to upload and analyze genomic sample data for our CE-IVD marked products. It enables a fully CE-IVD compliant workflow, from library preparation to variant identification (Figure 1). Once the samples are analyzed, IVD reports are created and can be downloaded from the web portal to support decision-making.

Analytical Performance

Analysis time from FASTQ: Max. 8 hours per 16 samples

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Observed (%)</th>
<th>Lower 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive Percent Agreement (PPA)</td>
<td>100</td>
<td>88.65</td>
</tr>
<tr>
<td>Negative Percent Agreement (NPA)</td>
<td>100</td>
<td>99.99</td>
</tr>
<tr>
<td>Overall Percent Agreement</td>
<td>100</td>
<td>-</td>
</tr>
<tr>
<td>Repeatability</td>
<td>100</td>
<td>-</td>
</tr>
<tr>
<td>Diagnostic sensitivity***</td>
<td>100</td>
<td>70.09</td>
</tr>
<tr>
<td>Diagnostic specificity***</td>
<td>100</td>
<td>77.19</td>
</tr>
</tbody>
</table>

*Based on analysis of fusion/exon skipping detection in 54 clinical FFPE samples, including 40 lung tumor samples and 14 derived from other solid tumors; status pre-determined by alternative NGS method(s) and compared with SOPHiA DDM™ Dx RNAtarget Oncology Solution outcome.

**Based on measurement of PPA/NPA in 32 replicates of a diluted reference samples, bearing 14 targeted rearrangements.

***Based on analysis of fusion/exon skipping detection in clinical study of 22 RNA FFPE lung tumor samples, performed by external site; status pre-determined by externally validated NGS method and compared with SOPHiA DDM™ Dx RNAtarget Oncology Solution outcome.

Global support at every step

We offer local support anywhere in the world. Our dedicated bioinformaticians help save time and resources, ensuring fast resolution of workflow disruptions. In addition, our Set Up Program provides assistance with application set up for fast and worry-free transition to routine testing.

Secure and unlimited data storage

The SOPHiA DDM™ Platform provides unlimited and unrestricted storage, while keeping data safe by applying the highest industrial standards of encryption in compliance with local data security policies.

Product codes: BS019KLLCSPY07-32

FFPE, formalin fixed, paraffin-embedded; IVD, in vitro diagnostic; NGS, next-generation sequencing.

1. Analysis time may vary depending on the number of samples multiplexed and server load.

This CE IVD-marked product is For In Vitro Diagnostic Use in Europe, Turkey and Israel markets. This product has not been cleared and approved by the U.S. FDA and may not be approved in some countries/regions. The CDS features are for Clinical Decision Support only and not for use as a primary diagnostic tool. Please contact SOPHiA GENETICS™ local Sales representatives to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS™ remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS™ use of third party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS™ and the owners of these trademarks. Any references by SOPHiA GENETICS™ to third party trademarks is to identify the corresponding third party goods and/or services and shall be considered nominative fair use under the trademark law.